Stock report · Delisted · NASDAQ
Spark Therapeutics, Inc. (ONCE)
Delisted Delisted – acquisition

ONCE no longer trades. Roche completed its acquisition of Spark Therapeutics on December 17, 2019, paying $114.50 per share in cash after a lengthy antitrust review.
Delisting details
- Exchange (former)
- NASDAQ
- Status
- Delisted – acquisition
- Delisted
- December 17, 2019
- Reason
- Acquired by Roche for $114.50 per share in cash
- Consideration
- $114.50 per share in cash
- Successor
- Roche Holding AG
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Philadelphia, Pennsylvania
About Spark Therapeutics, Inc.
Spark Therapeutics was a Philadelphia gene therapy company that developed one-time treatments for inherited diseases, especially those affecting the retina and blood. It grew out of gene therapy research at the Children's Hospital of Philadelphia, which helped launch the company in 2013. Its founders included researchers who had worked on gene therapy programs at the hospital for many years, and the company had its own manufacturing operations for viral vectors used in its treatments.
Spark went public on Nasdaq in January 2015 under the ticker ONCE, a reference to its goal of therapies given only once. Its lead product, Luxturna, treats vision loss caused by mutations in the RPE65 gene. In December 2017 Luxturna became the first FDA-approved gene therapy for an inherited disease in the United States, with a list price of about $850,000 for both eyes.
The company also worked on gene therapies for hemophilia A and B and for neurological conditions such as Huntington's disease, partnering with Pfizer on hemophilia B and licensing Luxturna rights outside the US to Novartis. These collaborations brought in cash and milestone payments that helped fund its research. Its hemophilia A candidate drew particular interest from investors and potential buyers.
In February 2019 Roche agreed to buy Spark for $114.50 per share in cash, about $4.3 billion, a large premium to the prior share price. Reviews by the US Federal Trade Commission and the UK competition authority pushed back the closing several times. Roche completed the deal on December 17, 2019, and Spark's shares were delisted. Spark operated as an independent unit within the Roche group in Philadelphia.
Spark Therapeutics FAQ
What happened to Spark Therapeutics stock?
Roche completed its acquisition of Spark Therapeutics on December 17, 2019, paying $114.50 per share in cash after a lengthy antitrust review.
Can I still buy ONCE stock?
No. ONCE is no longer listed on NASDAQ or any other U.S. exchange.
What did Spark Therapeutics shareholders receive?
Shareholders received $114.50 per share in cash.
ONCE no longer trades, so there is no live quote or chart. The information on this page is for reference only and is not investment advice; see our disclaimer.